Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZD2M
|
|||
| Former ID |
DCL000576
|
|||
| Drug Name |
MLN4924
|
|||
| Synonyms |
Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [1], [2] | |
| Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 2 | [2] | ||
| Advanced malignancy [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [3] | ||
| Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Investigative | [4] | ||
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H25N5O4S
|
|||
| Canonical SMILES |
C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N
|
|||
| InChI |
1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1
|
|||
| InChIKey |
MPUQHZXIXSTTDU-QXGSTGNESA-N
|
|||
| CAS Number |
CAS 905579-51-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:95028
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NEDD8-activating enzyme (NAE) | Target Info | Modulator | [5] |
| Ubiquitin-like protein Nedd8 (NEDD8) | Target Info | Inhibitor | [4] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Drug discovery: Fresh target for cancer therapy. Nature. 2009 Apr 9;458(7239):709-10. | |||
| REF 4 | Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834. | |||
| REF 5 | Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Cell Death Dis.2012 Sep 6;3:e386. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.